Possis Targets Q4 XVG Launch; AngioJet Stroke Indications Sought By 2004
This article was originally published in The Gray Sheet
Executive Summary
Possis Medical's AngioJet premarket approval application submission for expanded use to treat ischemic stroke is expected in 2004 at the earliest, the firm is forecasting.
You may also be interested in...
TriPath PREPmate Approval Lifts Stock 60%; OTC Index Outperforms Nasdaq
FDA approval of TriPath Imaging's PREPmate automated accessory for the AutoCyte PREP thin-layer sample preparation system combined with strong first-quarter earnings helped boost the company's stock price 60% in May. The issue advanced 3.27 points to close the month at 8.77.
Possis
Firm commences TIME 1 trial for ischemic stroke using AngioJet Rheolytic thrombectomy system, including the AngioJet NV150 catheter. The 30-patient trial is being conducted at six U.S. sites and should be complete in one year
Possis To Pursue Non-Coronary Uses For AngioJet Thrombectomy Device
Possis Medical intends to pursue non-cardiology applications for its AngioJet Rheolytic thrombectomy catheter once the company becomes profitable, expected "this time next year," according to President and CEO Robert Dutcher.